UCB S.A. · Brussels Belgium (Euronext Brussels: UCB)
| Allée De La Recherche 60 | Phone: +32-2-559-99-99 |
| Brussels | Fax: +32-2-559-99-00 |
| 1070 | |
| Belgium | 
Map This Company |
UCB S.A. Rankings
| Euronext 100 | BEL20 |
Company Description
You see, UCB wants to be a world leader when it comes to treating ailments related to the immune and central nervous systems (CNS). The company manufacturers prescription drugs to treat Crohn's disease, epilepsy, and Parkinson's disease. UCB's top products include Cimzia for Crohn's disease,Vimpat to treat epilepsy, and Neupro for Parkinson's disease. The company also makes allergy blockbuster Zyrtec. UCB has operations in nearly 30 countries, and markets its products through an internal sales force and through strategic relationships with other pharmaceutical companies. Marketing, manufacturing, and development partners include
UCB S.A. Reports
No subscription, no problem.
Download presentation-ready reports. From company profiles to the competitive landscape, Hoover's offers immediate access to individual reports.
Financials
| Company Type | Public - Euronext Brussels: UCB Headquarters |
|---|---|
| Fiscal Year-End | December |
| 2010 Employees | 8,898 |
Executives
38 executives listed for UCB S.A.'s Brussels, Belgium location.
| Chairman, Executive Committee, and CEO | Roch Doliveux | |
|---|---|---|
| Chairman | Karel Boone | |
| Vice Chair | Countess Diego du Monceau de Bergendal |